Appendices Refe Vitae_List of publications

Cover Page
The handle http://hdl.handle.net/1887/24412 holds various files of this Leiden University
dissertation
Author: Willemse, Peter-Paul M.
Title: Skeletal and metabolic complications of testicular germ cell tumours
Issue Date: 2014-03-06
Appendices
Reference List
Abbreviations
Acknowledgements
Curriculum Vitae
List of Publications
Appendices
REFERENCE LIST
1. Huyghe E, Matsuda T, Thonneau P: Increasing incidence of testicular cancer worldwide: a
review. J.Urol. 2003;170:5-11.
2. Post PN, Casparie MK, ten Kate FJ, et al: [The epidemiology of tumors of the testes in The
Netherlands: accurate rendering by the Registry of Histopathology and Cytopathology
(PALGA)]. Ned.Tijdschr.Geneeskd. 2004;148:1150-1154.
3. Goedert JJ, Purdue MP, McNeel TS, et al: Risk of germ cell tumors among men with HIV/
acquired immunodeficiency syndrome. Cancer Epidemiol.Biomarkers Prev. 2007;16:12661269.
4. Bul M, Roemeling S, Zeegers AG, et al: [The need for orchiopexy in the case of congenital
undescended testis]. Ned.Tijdschr.Geneeskd. 2009;153:980-983.
5. Holzbeierlein JM, Sogani PC, Sheinfeld J: Histology and clinical outcomes in patients with
bilateral testicular germ cell tumors: the Memorial Sloan Kettering Cancer Center experience
1950 to 2001. J.Urol. 2003;169:2122-2125.
6. Schaapveld M, van den Belt-Dusebout AW, Gietema JA, et al: Risk and prognostic significance
of metachronous contralateral testicular germ cell tumours. Br.J.Cancer 2012;107:1637-1643.
7. Hoei-Hansen CE, Holm M, Rajpert-De Meyts E, et al: Histological evidence of testicular
dysgenesis in contralateral biopsies from 218 patients with testicular germ cell cancer. J.Pathol.
2003;200:370-374.
8. Petersen PM, Skakkebaek NE, Rorth M, et al: Semen quality and reproductive hormones
before and after orchidectomy in men with testicular cancer. J.Urol. 1999;161:822-826.
9. Nord C, Bjoro T, Ellingsen D, et al: Gonadal hormones in long-term survivors 10 years after
treatment for unilateral testicular cancer. Eur.Urol. 2003;44:322-328.
10. Oliver RT, Mason MD, Mead GM, et al: Radiotherapy versus single-dose carboplatin in adjuvant
treatment of stage I seminoma: a randomised trial. Lancet 2005;366:293-300.
11. Einhorn LH, Donohue J: Cis-diamminedichloroplatinum, vinblastine, and bleomycin
combination chemotherapy in disseminated testicular cancer. Ann.Intern.Med. 1977;87:293298.
12. Saxman SB, Finch D, Gonin R, et al: Long-term follow-up of a phase III study of three versus
four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the
Indian University experience. J.Clin.Oncol. 1998;16:702-706.
13. de Wit R, Roberts JT, Wilkinson PM, et al: Equivalence of three or four cycles of bleomycin,
etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ
cell cancer: a randomized study of the European Organization for Research and Treatment of
Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.
J.Clin.Oncol. 2001;19:1629-1640.
14. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with
cisplatin, bleomycin, and either vinblastine or etoposide. N.Engl.J.Med. 1987;316:1435-1440.
15. Andreassen KE, Grotmol T, Cvancarova MS, et al: Risk of metachronous contralateral
testicular germ cell tumors: a population-based study of 7,102 Norwegian patients (19532007). Int.J.Cancer 2011;129:2867-2874.
16. Verdecchia A, Francisci S, Brenner H, et al: Recent cancer survival in Europe: a 2000-02
period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8:784-796.
17. Stang A, Jansen L, Trabert B, et al: Survival after a diagnosis of testicular germ cell cancers
in Germany and the United States, 2002-2006: a high resolution study by histology and age.
Cancer Epidemiol. 2013;37:492-497.
144
Reference List
18. Feldman DR, Bosl GJ, Sheinfeld J, et al: Medical treatment of advanced testicular cancer.
JAMA 2008;299:672-684.
19. Samuels ML, Holoye PY, Johnson DE: Bleomycin combination chemotherapy in the
management of testicular neoplasia. Cancer 1975;36:318-326.
20. Vogelzang NJ, Bosl GJ, Johnson K, et al: Raynaud’s phenomenon: a common toxicity after
combination chemotherapy for testicular cancer. Ann.Intern.Med. 1981;95:288-292.
21. Weijl NI, Rutten MF, Zwinderman AH, et al: Thromboembolic events during chemotherapy for
germ cell cancer: a cohort study and review of the literature. J.Clin.Oncol. 2000;18:2169-2178.
22. AnonymousStudy of the clinical efficiency of bleomycin in human cancer. Br.Med.J. 1970;2:643645.
23. van Barneveld PW, Veenstra G, Sleijfer DT, et al: Changes in pulmonary function during and
after bleomycin treatment in patients with testicular carcinoma. Cancer Chemother.Pharmacol.
1985;14:168-171.
24. Dentino M, Luft FC, Yum MN, et al: Long term effect of cis-diamminedichloride platinum
(CDDP) on renal function and structure in man. Cancer 1978;41:1274-1281.
25. Kreuser ED, Harsch U, Hetzel WD, et al: Chronic gonadal toxicity in patients with testicular
cancer after chemotherapy. Eur.J.Cancer Clin.Oncol. 1986;22:289-294.
26. Burgess MA, Einhorn LH, Gottlieb JA: Treatment of metastatic germ-cell tumors in men with
adriamycin, vincristine, and bleomycin. Cancer Treat.Rep. 1977;61:1447-1451.
27. Huddart RA, Norman A, Shahidi M, et al: Cardiovascular disease as a long-term complication
of treatment for testicular cancer. J.Clin.Oncol. 2003;21:1513-1523.
28. van den Belt-Dusebout AW, Nuver J, de WR, et al: Long-term risk of cardiovascular disease in
5-year survivors of testicular cancer. J.Clin.Oncol. 2006;24:467-475.
29. Haugnes HS, Wethal T, Aass N, et al: Cardiovascular risk factors and morbidity in long-term
survivors of testicular cancer: a 20-year follow-up study. J.Clin.Oncol. 2010;28:4649-4657.
30. Brennemann W, Stoffel-Wagner B, Helmers A, et al: Gonadal function of patients treated with
cisplatin based chemotherapy for germ cell cancer. J.Urol. 1997;158:844-850.
31. Eberhard J, Stahl O, Giwercman Y, et al: Impact of therapy and androgen receptor polymorphism
on sperm concentration in men treated for testicular germ cell cancer: a longitudinal study.
Hum.Reprod. 2004;19:1418-1425.
32. Hansen SW, Berthelsen JG, von der MH: Long-term fertility and Leydig cell function in patients
treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance.
J.Clin.Oncol. 1990;8:1695-1698.
33. Gerl A, Muhlbayer D, Hansmann G, et al: The impact of chemotherapy on Leydig cell function
in long term survivors of germ cell tumors. Cancer 2001;91:1297-1303.
34. Hansen SW, Olsen N: Raynaud’s phenomenon in patients treated with cisplatin, vinblastine,
and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold. J.Clin.
Oncol. 1989;7:940-942.
35. Aydiner A, Aytekin Y, Topuz E: Effects of cisplatin on testicular tissue and the Leydig cellpituitary axis. Oncology 1997;54:74-78.
36. Berger CC, Bokemeyer C, Schuppert F, et al: Endocrinological late effects after chemotherapy
for testicular cancer. Br.J.Cancer 1996;73:1108-1114.
37. Imam SK, Shahid SK, Hassan A, et al: Frequency of the metabolic syndrome in type 2
diabetic subjects attending the diabetes clinic of a tertiary care hospital. J.Pak.Med.Assoc.
2007;57:239-242.
38. Ingelsson E, Arnlov J, Lind L, et al: Metabolic syndrome and risk for heart failure in middle-aged
men. Heart 2006;92:1409-1413.
145
Appendices
39. Hu G, Qiao Q, Tuomilehto J, et al: Prevalence of the metabolic syndrome and its relation to
all-cause and cardiovascular mortality in nondiabetic European men and women. Arch.Intern.
Med. 2004;164:1066-1076.
40. Report of a WHO Consultation. Defenition, Diagnosis and Classification of Diabetes Mellitus
and its Complications. 1-1-1999. World Health Organization.
41. Balkau B, Charles MA: Comment on the provisional report from the WHO consultation.
European Group for the Study of Insulin Resistance (EGIR). Diabet.Med. 1999;16:442-443.
42. AnonymousThird Report of the National Cholesterol Education Program (NCEP) Expert Panel
on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment
Panel III) final report. Circulation 2002;106:3143-3421.
43. Alberti KG, Zimmet P, Shaw J: The metabolic syndrome--a new worldwide definition. Lancet
2005;366:1059-1062.
44. Galassi A, Reynolds K, He J: Metabolic syndrome and risk of cardiovascular disease: a metaanalysis. Am.J.Med. 2006;119:812-819.
45. Gami AS, Witt BJ, Howard DE, et al: Metabolic syndrome and risk of incident cardiovascular
events and death: a systematic review and meta-analysis of longitudinal studies. J.Am.Coll.
Cardiol. 2007;49:403-414.
46. Nuver J, Smit AJ, Wolffenbuttel BH, et al: The metabolic syndrome and disturbances in hormone
levels in long-term survivors of disseminated testicular cancer. J.Clin.Oncol. 2005;23:37183725.
47. Wethal T, Kjekshus J, Roislien J, et al: Treatment-related differences in cardiovascular risk
factors in long-term survivors of testicular cancer. J.Cancer Surviv. 2007;1:8-16.
48. Haugnes HS, Aass N, Fossa SD, et al: Components of the metabolic syndrome in long-term
survivors of testicular cancer. Ann.Oncol. 2007;18:241-248.
49. de Haas EC, Altena R, Boezen HM, et al: Early development of the metabolic syndrome after
chemotherapy for testicular cancer. Ann.Oncol. 2013;24:749-755.
50. Stutz JA, Barry BP, Maslanka W, et al: Bone density: is it affected by orchidectomy and
radiotherapy given for stage I seminoma of the testis? Clin.Oncol.(R.Coll.Radiol.) 1998;10:4449.
51. Brown JE, Ellis SP, Silcocks P, et al: Effect of chemotherapy on skeletal health in male survivors
from testicular cancer and lymphoma. Clin.Cancer Res. 2006;12:6480-6486.
52. Murugaesu N, Powles T, Bestwick J, et al: Long-term follow-up of testicular cancer patients
shows no predisposition to osteoporosis. Osteoporos.Int. 2009;20:1627-1630.
53. Ondrusova M, Ondrus D, Dusek L, et al: Damage of hormonal function and bone metabolism
in long-term survivors of testicular cancer. Neoplasma 2009;56:473-479.
54. Weijl NI, Hopman GD, Wipkink-Bakker A, et al: Cisplatin combination chemotherapy induces a
fall in plasma antioxidants of cancer patients. Ann.Oncol. 1998;9:1331-1337.
55. Weijl NI, Elsendoorn TJ, Moison RM, et al: Non-protein bound iron release during chemotherapy
in cancer patients. Clin.Sci.(Lond) 2004;106:475-484.
56. Linpisarn S, Satoh K, Mikami T, et al: Effects of iron on lipid peroxidation. Int.J.Hematol.
1991;54:181-188.
57. Dabbagh AJ, Mannion T, Lynch SM, et al: The effect of iron overload on rat plasma and liver
oxidant status in vivo. Biochem.J. 1994;300 ( Pt 3):799-803.
58. Anderson GJ: Mechanisms of iron loading and toxicity. Am.J.Hematol. 2007;82:1128-1131.
59. Kohgo Y, Ikuta K, Ohtake T, et al: Body iron metabolism and pathophysiology of iron overload.
Int.J.Hematol. 2008;88:7-15.
146
Reference List
60. Raghavan D, Cox K, Childs A, et al: Hypercholesterolemia after chemotherapy for testis cancer.
J.Clin.Oncol. 1992;10:1386-1389.
61. de Haas EC, Oosting SF, Lefrandt JD, et al: The metabolic syndrome in cancer survivors.
Lancet Oncol. 2010;11:193-203.
62. Montiel M, Urso L, de la Blanca EP, et al: Cisplatin reduces endothelial cell migration via
regulation of type 2-matrix metalloproteinase activity. Cell Physiol Biochem. 2009;23:441-448.
63. Nuver J, de Haas EC, Van ZM, et al: Vascular damage in testicular cancer patients: a study on
endothelial activation by bleomycin and cisplatin in vitro. Oncol.Rep. 2010;23:247-253.
64. Burkhardt A, Holtje WJ, Gebbers JO: Vascular lesions following perfusion with bleomycin.
Electron-microscopic observations. Virchows Arch.A Pathol.Anat.Histol. 1976;372:227-236.
65. Heier MS, Nilsen T, Graver V, et al: Raynaud’s phenomenon after combination chemotherapy
of testicular cancer, measured by laser Doppler flowmetry. A pilot study. Br.J.Cancer
1991;63:550-552.
66. Amar J, Ruidavets JB, Chamontin B, et al: Arterial stiffness and cardiovascular risk factors in a
population-based study. J.Hypertens. 2001;19:381-387.
67. Maldonado J, Pereira T, Polonia J, et al: Arterial stiffness predicts cardiovascular outcome
in a low-to-moderate cardiovascular risk population: the EDIVA (Estudo de DIstensibilidade
VAscular) project. J.Hypertens. 2011;29:669-675.
68. Joly L, Perret-Guillaume C, Kearney-Schwartz A, et al: Pulse wave velocity assessment by
external noninvasive devices and phase-contrast magnetic resonance imaging in the obese.
Hypertension 2009;54:421-426.
69. Fernandez FG, Ritter J, Goodwin JW, et al: Effect of steatohepatitis associated with irinotecan
or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J.Am.Coll.Surg.
2005;200:845-853.
70. Pollera CF, Ameglio F, Nardi M, et al: Cisplatin-induced hepatic toxicity. J.Clin.Oncol.
1987;5:318-319.
71. Shuman WP, Morris LL, Leonetti DL, et al: Abnormal body fat distribution detected by
computed tomography in diabetic men. Invest Radiol. 1986;21:483-487.
72. Peiris AN, Sothmann MS, Hoffmann RG, et al: Adiposity, fat distribution, and cardiovascular
risk. Ann.Intern.Med. 1989;110:867-872.
73. Hunter GR, Snyder SW, Kekes-Szabo T, et al: Intra-abdominal adipose tissue values associated
with risk of possessing elevated blood lipids and blood pressure. Obes.Res. 1994;2:563-568.
74. Einhorn EH: Testicular cancer: an oncological success story. Clin.Cancer Res. 1997;3:26302632.
75. de Forni M, Armand JP: Cardiotoxicity of chemotherapy. Curr.Opin.Oncol. 1994;6:340-344.
76. Yeh ET, Tong AT, Lenihan DJ, et al: Cardiovascular complications of cancer therapy: diagnosis,
pathogenesis, and management. Circulation 2004;109:3122-3131.
77. Carver JR, Shapiro CL, Ng A, et al: American Society of Clinical Oncology clinical evidence
review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
J.Clin.Oncol. 2007;25:3991-4008.
78. Nuver J, Smit AJ, Postma A, et al: The metabolic syndrome in long-term cancer survivors, an
important target for secondary preventive measures. Cancer Treat.Rev. 2002;28:195-214.
79. Alberti KG, Zimmet P, Shaw J: Metabolic syndrome--a new world-wide definition. A Consensus
Statement from the International Diabetes Federation. Diabet.Med. 2006;23:469-480.
80. Skakkebaek NE, Rajpert-De ME, Jorgensen N, et al: Testicular cancer trends as ‘whistle
blowers’ of testicular developmental problems in populations. Int.J.Androl 2007;30:198-204.
147
Appendices
81. Ivell R, nand-Ivell R: Biology of insulin-like factor 3 in human reproduction. Hum.Reprod.
Update. 2009;15:463-476.
82. Wilson PW, Castelli WP, Kannel WB: Coronary risk prediction in adults (the Framingham Heart
Study). Am.J.Cardiol. 1987;59:91G-94G.
83. Conroy RM, Pyorala K, Fitzgerald AP, et al: Estimation of ten-year risk of fatal cardiovascular
disease in Europe: the SCORE project. Eur.Heart J. 2003;24:987-1003.
84. Lackner JE, Mark I, Schatzl G, et al: Hypogonadism and androgen deficiency symptoms in
testicular cancer survivors. Urology 2007;69:754-758.
85. Rathmann W, Haastert B, Icks A, et al: Prevalence of the metabolic syndrome in the elderly
population according to IDF, WHO, and NCEP definitions and associations with C-reactive
protein: the KORA Survey 2000. Diabetes Care 2006;29:461-.
86. Haugnes HS, Aass N, Fossa SD, et al: Predicted cardiovascular mortality and reported
cardiovascular morbidity in testicular cancer survivors. J.Cancer Surviv. 2008;2:128-137.
87. de Visser CL, Bilo HJ, Thomsen TF, et al: Prediction of coronary heart disease: a comparison
between the Copenhagen risk score and the Framingham risk score applied to a Dutch
population. J.Intern.Med. 2003;253:553-562.
88. Krege S, Beyer J, Souchon R, et al: European consensus conference on diagnosis and
treatment of germ cell cancer: a report of the second meeting of the European Germ Cell
Cancer Consensus group (EGCCCG): part I. Eur.Urol. 2008;53:478-496.
89. Williams DH, Karpman E, Sander JC, et al: Pretreatment semen parameters in men with
cancer. J.Urol. 2009;181:736-740.
90. Muller M, Grobbee DE, den Tonkelaar I, et al: Endogenous sex hormones and metabolic
syndrome in aging men. J.Clin.Endocrinol.Metab 2005;90:2618-2623.
91. Kupelian V, Page ST, Araujo AB, et al: Low sex hormone-binding globulin, total testosterone,
and symptomatic androgen deficiency are associated with development of the metabolic
syndrome in nonobese men. J.Clin.Endocrinol.Metab 2006;91:843-850.
92. Miner MM, Seftel AD: Testosterone and ageing: what have we learned since the Institute of
Medicine report and what lies ahead? Int.J.Clin.Pract. 2007;61:622-632.
93. Fernandez-Balsells MM, Murad MH, Lane M, et al: Clinical review 1: Adverse effects of
testosterone therapy in adult men: a systematic review and meta-analysis. J.Clin.Endocrinol.
Metab 2010;95:2560-2575.
94. Monroe AK, Dobs AS: The effect of androgens on lipids. Curr.Opin.Endocrinol.Diabetes Obes.
2013;20:132-139.
95. Snyder PJ, Peachey H, Berlin JA, et al: Effects of testosterone replacement in hypogonadal
men. J.Clin.Endocrinol.Metab 2000;85:2670-2677.
96. Aversa A, Bruzziches R, Francomano D, et al: Efficacy and safety of two different testosterone
undecanoate formulations in hypogonadal men with metabolic syndrome. J.Endocrinol.Invest
2010;33:776-783.
97. Lakshman KM, Basaria S: Safety and efficacy of testosterone gel in the treatment of male
hypogonadism. Clin.Interv.Aging 2009;4:397-412.
98. Stefenelli T, Kuzmits R, Ulrich W, et al: Acute vascular toxicity after combination chemotherapy
with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur.Heart J. 1988;9:552-556.
99. Bjorntorp P: Metabolic implications of body fat distribution. Diabetes Care 1991;14:1132-1143.
100. Brook RD, Bard RL, Rubenfire M, et al: Usefulness of visceral obesity (waist/hip ratio) in predicting
vascular endothelial function in healthy overweight adults. Am.J.Cardiol. 2001;88:1264-1269.
101. Despres JP: Cardiovascular disease under the influence of excess visceral fat. Crit Pathw.
Cardiol. 2007;6:51-59.
148
Reference List
102. Ritchie SA, Connell JM: The link between abdominal obesity, metabolic syndrome and
cardiovascular disease. Nutr.Metab Cardiovasc.Dis. 2007;17:319-326.
103. Fischbach F, Bruhn H: Assessment of in vivo 1H magnetic resonance spectroscopy in the liver:
a review. Liver Int. 2008;28:297-307.
104. van der Meer RW, Hammer S, Lamb HJ, et al: Effects of short-term high-fat, high-energy
diet on hepatic and myocardial triglyceride content in healthy men. J.Clin.Endocrinol.Metab
2008;93:2702-2708.
105. Hamaguchi M, Kojima T, Takeda N, et al: The metabolic syndrome as a predictor of nonalcoholic
fatty liver disease. Ann.Intern.Med. 2005;143:722-728.
106. Matthews DR, Hosker JP, Rudenski AS, et al: Homeostasis model assessment: insulin
resistance and beta-cell function from fasting plasma glucose and insulin concentrations in
man. Diabetologia 1985;28:412-419.
107. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its
complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a
WHO consultation. Diabet.Med. 1998;15:539-553.
108. van der Meer RW, Diamant M, Westenberg JJ, et al: Magnetic resonance assessment of aortic
pulse wave velocity, aortic distensibility, and cardiac function in uncomplicated type 2 diabetes
mellitus. J.Cardiovasc.Magn Reson. 2007;9:645-651.
109. Szczepaniak LS, Nurenberg P, Leonard D, et al: Magnetic resonance spectroscopy to
measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population.
Am.J.Physiol Endocrinol.Metab 2005;288:E462-E468.
110. Mahmood S, Taketa K, Imai K, et al: Association of fatty liver with increased ratio of visceral to
subcutaneous adipose tissue in obese men. Acta Med.Okayama 1998;52:225-231.
111. Machann J, Thamer C, Schnoedt B, et al: Hepatic lipid accumulation in healthy subjects: a
comparative study using spectral fat-selective MRI and volume-localized 1H-MR spectroscopy.
Magn Reson.Med. 2006;55:913-917.
112. Qi J, Fong Y, Saltz L, et al: Serial measurement of hepatic lipids during chemotherapy in
patients with colorectal cancer: a 1 H MRS study. NMR Biomed. 2013;26:204-212.
113. Kohn S, Fradis M, Podoshin L, et al: Endothelial injury of capillaries in the stria vascularis of
guinea pigs treated with cisplatin and gentamicin. Ultrastruct.Pathol. 1997;21:289-299.
114. Webb DR, Khunti K, Silverman R, et al: Impact of metabolic indices on central artery stiffness:
independent association of insulin resistance and glucose with aortic pulse wave velocity.
Diabetologia 2010;53:1190-1198.
115. van der Meer RW, Hammer S, Smit JW, et al: Short-term caloric restriction induces accumulation
of myocardial triglycerides and decreases left ventricular diastolic function in healthy subjects.
Diabetes 2007;56:2849-2853.
116. Fong AC, Cheung NW: The high incidence of steroid-induced hyperglycaemia in hospital.
Diabetes Res.Clin.Pract. 2013;99:277-280.
117. Altena R, de Haas EC, Nuver J, et al: Evaluation of sub-acute changes in cardiac function after
cisplatin-based combination chemotherapy for testicular cancer. Br.J.Cancer 2009;100:18611866.
118. Battiprolu PK, Gillette TG, Wang ZV, et al: Diabetic Cardiomyopathy: Mechanisms and
Therapeutic Targets. Drug Discov.Today Dis.Mech. 2010;7:e135-e143.
119. Dinh W, Lankisch M, Nickl W, et al: Insulin resistance and glycemic abnormalities are associated
with deterioration of left ventricular diastolic function: a cross-sectional study. Cardiovasc.
Diabetol. 2010;9:63-.
149
Appendices
120. Devaraj S, Kumaresan PR, Jialal I: C-reactive protein induces release of both endothelial
microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial
dysfunction. Clin.Chem. 2011;57:1757-1761.
121. Altena R, Hummel YM, Nuver J, et al: Longitudinal changes in cardiac function after cisplatinbased chemotherapy for testicular cancer. Ann.Oncol. 2011;22:2286-2293.
122. van der Meer RW, Doornbos J, Kozerke S, et al: Metabolic imaging of myocardial triglyceride
content: reproducibility of 1H MR spectroscopy with respiratory navigator gating in volunteers.
Radiology 2007;245:251-257.
123. Rijzewijk LJ, van der Meer RW, Smit JW, et al: Myocardial steatosis is an independent predictor
of diastolic dysfunction in type 2 diabetes mellitus. J.Am.Coll.Cardiol. 2008;52:1793-1799.
124. Katz A, Nambi SS, Mather K, et al: Quantitative insulin sensitivity check index: a simple, accurate
method for assessing insulin sensitivity in humans. J.Clin.Endocrinol.Metab 2000;85:24022410.
125. Willemse PM, van der Meer RW, Burggraaf J, et al: Abdominal visceral and subcutaneous
fat increase, insulin resistance and hyperlipidemia in testicular cancer patients treated with
cisplatin-based chemotherapy. Acta Oncol. 2013;-.
126. Lamb HJ, Doornbos J, van d, V, et al: Echo planar MRI of the heart on a standard system:
validation of measurements of left ventricular function and mass. J.Comput.Assist.Tomogr.
1996;20:942-949.
127. Pattynama PM, Lamb HJ, van d, V, et al: Left ventricular measurements with cine and spinecho MR imaging: a study of reproducibility with variance component analysis. Radiology
1993;187:261-268.
128. Paelinck BP, de RA, Bax JJ, et al: Feasibility of tissue magnetic resonance imaging: a pilot
study in comparison with tissue Doppler imaging and invasive measurement. J.Am.Coll.
Cardiol. 2005;45:1109-1116.
129. Naressi A, Couturier C, Castang I, et al: Java-based graphical user interface for MRUI, a
software package for quantitation of in vivo/medical magnetic resonance spectroscopy
signals. Comput.Biol.Med. 2001;31:269-286.
130. Jonker JT, Lamb HJ, van der Meer RW, et al: Pioglitazone compared with metformin increases
pericardial fat volume in patients with type 2 diabetes mellitus. J.Clin.Endocrinol.Metab
2010;95:456-460.
131. Meinardi MT, Gietema JA, van der Graaf WT, et al: Cardiovascular morbidity in long-term
survivors of metastatic testicular cancer. J.Clin.Oncol. 2000;18:1725-1732.
132. Nuver J, Smit AJ, Sleijfer DT, et al: Left ventricular and cardiac autonomic function in survivors
of testicular cancer. Eur.J.Clin.Invest 2005;35:99-103.
133. Nuver J, Smit AJ, van der Meer J, et al: Acute chemotherapy-induced cardiovascular changes
in patients with testicular cancer. J.Clin.Oncol. 2005;23:9130-9137.
134. Monsuez JJ: Detection and prevention of cardiac complications of cancer chemotherapy.
Arch.Cardiovasc.Dis. 2012;105:593-604.
135. Nuver J, Smit AJ, Sleijfer DT, et al: Microalbuminuria, decreased fibrinolysis, and inflammation
as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer.
Eur.J.Cancer 2004;40:701-706.
136. Brutsaert DL: Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile
performance, and rhythmicity. Physiol Rev. 2003;83:59-115.
137. Despres JP, Lemieux I: Abdominal obesity and metabolic syndrome. Nature 2006;444:881887.
150
Reference List
138. Mathieu P, Pibarot P, Larose E, et al: Visceral obesity and the heart. Int.J.Biochem.Cell Biol.
2008;40:821-836.
139. Verma S, Li SH, Wang CH, et al: Resistin promotes endothelial cell activation: further evidence
of adipokine-endothelial interaction. Circulation 2003;108:736-740.
140. Rijzewijk LJ, van der Meer RW, Lamb HJ, et al: Altered myocardial substrate metabolism and
decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with
cardiac positron emission tomography and magnetic resonance imaging. J.Am.Coll.Cardiol.
2009;54:1524-1532.
141. Voulgari C, Papadogiannis D, Tentolouris N: Diabetic cardiomyopathy: from the pathophysiology
of the cardiac myocytes to current diagnosis and management strategies. Vasc.Health Risk
Manag. 2010;6:883-903.
142. Bajraktari G, Koltai MS, Ademaj F, et al: Relationship between insulin resistance and left
ventricular diastolic dysfunction in patients with impaired glucose tolerance and type 2
diabetes. Int.J.Cardiol. 2006;110:206-211.
143. Kankaanpaa M, Lehto HR, Parkka JP, et al: Myocardial triglyceride content and epicardial fat
mass in human obesity: relationship to left ventricular function and serum free fatty acid levels.
J.Clin.Endocrinol.Metab 2006;91:4689-4695.
144. Hammer S, Snel M, Lamb HJ, et al: Prolonged caloric restriction in obese patients with type 2
diabetes mellitus decreases myocardial triglyceride content and improves myocardial function.
J.Am.Coll.Cardiol. 2008;52:1006-1012.
145. Richardson DR, Ponka P: The molecular mechanisms of the metabolism and transport of iron
in normal and neoplastic cells. Biochim.Biophys.Acta 1997;1331:1-40.
146. Batey RG, Lai Chung FP, Shamir S, et al: A non-transferrin-bound serum iron in idiopathic
hemochromatosis. Dig.Dis.Sci. 1980;25:340-346.
147. Grootveld M, Bell JD, Halliwell B, et al: Non-transferrin-bound iron in plasma or serum from
patients with idiopathic hemochromatosis. Characterization by high performance liquid
chromatography and nuclear magnetic resonance spectroscopy. J.Biol.Chem. 1989;264:44174422.
148. Loreal O, Gosriwatana I, Guyader D, et al: Determination of non-transferrin-bound iron in
genetic hemochromatosis using a new HPLC-based method. J.Hepatol. 2000;32:727-733.
149. de Valk B., Addicks MA, Gosriwatana I, et al: Non-transferrin-bound iron is present in serum of
hereditary haemochromatosis heterozygotes. Eur.J.Clin.Invest 2000;30:248-251.
150. Schafer AI, Cheron RG, Dluhy R, et al: Clinical consequences of acquired transfusional iron
overload in adults. N.Engl.J.Med. 1981;304:319-324.
151. Sullivan JL: Iron in arterial plaque: modifiable risk factor for atherosclerosis. Biochim.Biophys.
Acta 2009;1790:718-723.
152. Minqin R, Rajendran R, Pan N, et al: The iron chelator desferrioxamine inhibits atherosclerotic
lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit.
Free Radic.Biol.Med. 2005;38:1206-1211.
153. Osanto S, Bukman A, Van HF, et al: Long-term effects of chemotherapy in patients with
testicular cancer. J.Clin.Oncol. 1992;10:574-579.
154. Fossa SD, Oldenburg J, Dahl AA: Short- and long-term morbidity after treatment for testicular
cancer. BJU.Int. 2009;104:1418-1422.
155. International Germ Cell Consensus Classification: A prognostic factor-based staging system
for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J.Clin.
Oncol. 1997;15:594-603.
151
Appendices
156. Kolb AM, Smit NP, Lentz-Ljuboje R, et al: Non-transferrin bound iron measurement is influenced
by chelator concentration. Anal.Biochem. 2009;385:13-19.
157. Alexopoulos CG, Chalevelakis G, Katsoulis C, et al: Adverse effect of cisdiamminedichloroplatinum II (CDDP) on porphyrin metabolism in man. Cancer Chemother.
Pharmacol. 1986;17:165-170.
158. Pollera CF, Ameglio F, Nardi M, et al: Dose and schedule effects of cisplatin on the related
acute iron changes. Oncology 1990;47:133-138.
159. de Valk B, Marx JJ: Iron, atherosclerosis, and ischemic heart disease. Arch.Intern.Med.
1999;159:1542-1548.
160. Day SM, Duquaine D, Mundada LV, et al: Chronic iron administration increases vascular
oxidative stress and accelerates arterial thrombosis. Circulation 2003;107:2601-2606.
161. Kartikasari AE, Georgiou NA, Visseren FL, et al: Endothelial activation and induction of monocyte
adhesion by nontransferrin-bound iron present in human sera. FASEB J. 2006;20:353-355.
162. Gordon LI, Brown SG, Tallman MS, et al: Sequential changes in serum iron and ferritin in
patients undergoing high-dose chemotherapy and radiation with autologous bone marrow
transplantation: possible implications for treatment related toxicity. Free Radic.Biol.Med.
1995;18:383-389.
163. Gordeuk VR, Brittenham GM: Bleomycin-reactive iron in patients with acute non-lymphocytic
leukemia. FEBS Lett. 1992;308:4-6.
164. Araujo JA, Romano EL, Brito BE, et al: Iron overload augments the development of
atherosclerotic lesions in rabbits. Arterioscler.Thromb.Vasc.Biol. 1995;15:1172-1180.
165. Dufour P, Bergerat JP, Eber M, et al: Cisplatin-induced anemia: a potential interference with
iron metabolism at erythroid progenitors level. Anti-cancer Drugs 1990;1:49-54.
166. Mandal R, Kalke R, Li XF: Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin
and the resulting release of a heme group. Chem.Res.Toxicol. 2004;17:1391-1397.
167. Miyamoto Y, Shimada K, Sakaguchi Y, et al: Cisplatin (CDDP)-induced acute toxicity in an
experimental model of hepatic fibrosis. J.Toxicol.Sci. 2007;32:311-319.
168. Liao Y, Lu X, Lu C, et al: Selection of agents for prevention of cisplatin-induced hepatotoxicity.
Pharmacol.Res. 2008;57:125-131.
169. Morley JE, Patrick P, Perry HM, III: Evaluation of assays available to measure free testosterone.
Metabolism 2002;51:554-559.
170. Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of simple methods for the
estimation of free testosterone in serum. J.Clin.Endocrinol.Metab 1999;84:3666-3672.
171. Holick MF: Vitamin D deficiency. N.Engl.J.Med. 2007;357:266-281.
172. Roux C, Bischoff-Ferrari HA, Papapoulos SE, et al: New insights into the role of vitamin D and
calcium in osteoporosis management: an expert roundtable discussion. Curr.Med.Res.Opin.
2008;24:1363-1370.
173. Looker AC, Wahner HW, Dunn WL, et al: Proximal femur bone mineral levels of US adults.
Osteoporos.Int. 1995;5:389-409.
174. World Health Organisation. Assessment of fracture risk and its application to screening for
postmenopausal osteoporosis. 1994.
175. Genant HK, Wu CY, Van KC, et al: Vertebral fracture assessment using a semiquantitative
technique. J.Bone Miner.Res. 1993;8:1137-1148.
176. Delmas PD, Genant HK, Crans GG, et al: Severity of prevalent vertebral fractures and the
risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone
2003;33:522-532.
152
Reference List
177. Black DM, Palermo L, Nevitt MC, et al: Comparison of methods for defining prevalent vertebral
deformities: the Study of Osteoporotic Fractures. J.Bone Miner.Res. 1995;10:890-902.
178. Burger H, van Daele PL, Algra D, et al: Vertebral deformities as predictors of non-vertebral
fractures. BMJ 1994;309:991-992.
179. Hasserius R, Karlsson MK, Nilsson BE, et al: Prevalent vertebral deformities predict increased
mortality and increased fracture rate in both men and women: a 10-year population-based
study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis
Study. Osteoporos.Int. 2003;14:61-68.
180. Pongchaiyakul C, Nguyen ND, Jones G, et al: Asymptomatic vertebral deformity as a major risk
factor for subsequent fractures and mortality: a long-term prospective study. J.Bone Miner.
Res. 2005;20:1349-1355.
181. Wainwright SA, Marshall LM, Ensrud KE, et al: Hip fracture in women without osteoporosis.
J.Clin.Endocrinol.Metab 2005;90:2787-2793.
182. Ferrar L, Jiang G, Cawthon PM, et al: Identification of vertebral fracture and non-osteoporotic
short vertebral height in men: the MrOS study. J.Bone Miner.Res. 2007;22:1434-1441.
183. van Staa TP, Laan RF, Barton IP, et al: Bone density threshold and other predictors of vertebral
fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48:3224-3229.
184. Petersen PM, Giwercman A, Skakkebaek NE, et al: Gonadal function in men with testicular
cancer. Semin.Oncol. 1998;25:224-233.
185. Palmieri G, Lotrecchiano G, Ricci G, et al: Gonadal function after multimodality treatment in
men with testicular germ cell cancer. Eur.J.Endocrinol. 1996;134:431-436.
186. van Casteren NJ, Boellaard WP, Romijn JC, et al: Gonadal dysfunction in male cancer patients
before cytotoxic treatment. Int.J.Androl 2009;-.
187. Iqbal J, Sun L, Kumar TR, et al: Follicle-stimulating hormone stimulates TNF production from
immune cells to enhance osteoblast and osteoclast formation. Proc.Natl.Acad.Sci.U.S.A
2006;103:14925-14930.
188. Sun L, Peng Y, Sharrow AC, et al: FSH directly regulates bone mass. Cell 2006;125:247-260.
189. Baron R: FSH versus estrogen: who’s guilty of breaking bones? Cell Metab 2006;3:302-305.
190. Williams GR: Hypogonadal bone loss: sex steroids or gonadotrophins? Endocrinology
2007;148:2610-2612.
191. Skakkebaek NE, Rajpert-De ME, Main KM: Testicular dysgenesis syndrome: an increasingly
common developmental disorder with environmental aspects. Hum.Reprod. 2001;16:972-978.
192. Richiardi L, Akre O: Fertility among brothers of patients with testicular cancer. Cancer
Epidemiol.Biomarkers Prev. 2005;14:2557-2562.
193. Ismail AA, O’Neill TW, Cooper C, et al: Risk factors for vertebral deformities in men: relationship
to number of vertebral deformities. European Vertebral Osteoporosis Study Group. J.Bone
Miner.Res. 2000;15:278-283.
194. Lunt M, Felsenberg D, Reeve J, et al: Bone density variation and its effects on risk of vertebral
deformity in men and women studied in thirteen European centers: the EVOS Study. J.Bone
Miner.Res. 1997;12:1883-1894.
195. Lunt M, O’Neill TW, Felsenberg D, et al: Characteristics of a prevalent vertebral deformity
predict subsequent vertebral fracture: results from the European Prospective Osteoporosis
Study (EPOS). Bone 2003;33:505-513.
196. McCloskey EV, Spector TD, Eyres KS, et al: The assessment of vertebral deformity: a method
for use in population studies and clinical trials. Osteoporos.Int. 1993;3:138-147.
197. Pluijm SM, Tromp AM, Smit JH, et al: Consequences of vertebral deformities in older men and
women. J.Bone Miner.Res. 2000;15:1564-1572.
153
Appendices
198. Samelson EJ, Hannan MT, Zhang Y, et al: Incidence and risk factors for vertebral fracture in
women and men: 25-year follow-up results from the population-based Framingham study.
J.Bone Miner.Res. 2006;21:1207-1214.
199. Szulc P, Munoz F, Marchand F, et al: Semiquantitative evaluation of prevalent vertebral
deformities in men and their relationship with osteoporosis: the MINOS study. Osteoporos.Int.
2001;12:302-310.
200. Pfeilschifter J, Diel IJ: Osteoporosis due to cancer treatment: pathogenesis and management.
J.Clin.Oncol. 2000;18:1570-1593.
201. Willemse PM, Hamdy NA, van WL, et al: Prevalence of vertebral fractures independent of BMD
and anti-cancer treatment in patients with testicular germ cell tumors. J.Clin.Endocrinol.Metab
2010;95:4933-4942.
202. Baylink DJ: Glucocorticoid-induced osteoporosis. N.Engl.J.Med. 1983;309:306-308.
203. Fisher DE, Bickel WH: Corticosteroid-induced avascular necrosis. A clinical study of seventyseven patients. J.Bone Joint Surg.Am. 1971;53:859-873.
204. Petersen PM, Skakkebaek NE, Vistisen K, et al: Semen quality and reproductive hormones
before orchidectomy in men with testicular cancer. J.Clin.Oncol. 1999;17:941-947.
205. Bandak M, Aksglaede L, Juul A, et al: The pituitary-Leydig cell axis before and after
orchidectomy in patients with stage I testicular cancer. Eur.J.Cancer 2011;47:2585-2591.
206. Huddart RA, Norman A, Moynihan C, et al: Fertility, gonadal and sexual function in survivors of
testicular cancer. Br.J.Cancer 2005;93:200-207.
207. Canalis E, Mazziotti G, Giustina A, et al: Glucocorticoid-induced osteoporosis: pathophysiology
and therapy. Osteoporos.Int. 2007;18:1319-1328.
208. Weinstein RS: Glucocorticoid-induced osteoporosis. Rev.Endocr.Metab Disord. 2001;2:65-73.
209. Tobias J, Chambers TJ: Glucocorticoids impair bone resorptive activity and viability of
osteoclasts disaggregated from neonatal rat long bones. Endocrinology 1989;125:1290-1295.
210. Willemse PM, Burggraaf J, Hamdy NA, et al: Prevalence of the metabolic syndrome and
cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors.
Br.J.Cancer 2013;109:60-67.
211. Koc G, Divrik TR, Unlu N, et al: Does cisplatin-based chemotherapy effect on blood lipid
levels of patients with germ cell testicular tumor in long-term follow-up? Int.Urol.Nephrol.
2011;43:1095-1100.
212. Rasmussen F, Gunnell D, Ekbom A, et al: Birth weight, adult height, and testicular cancer:
cohort study of 337,249 Swedish young men. Cancer Causes Control 2003;14:595-598.
213. Dieckmann KP, Hartmann JT, Classen J, et al: Is increased body mass index associated with
the incidence of testicular germ cell cancer? J.Cancer Res.Clin.Oncol. 2009;135:731-738.
214. Miner MM, Sadovsky R: Evolving issues in male hypogonadism: evaluation, management, and
related comorbidities. Cleve.Clin.J.Med. 2007;74 Suppl 3:S38-S46.
215. Willemse PM, Burggraaf J, Hamdy NA and Osanto S: Reply: ‘Comment on Prevalence of the
metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ
cell tumour survivors’. Br.J.Cancer 2013;109:2503-2504.
216. Grundy SM, Brewer HB, Jr., Cleeman JI, et al: Definition of metabolic syndrome: Report of the
National Heart, Lung, and Blood Institute/American Heart Association conference on scientific
issues related to definition. Circulation 2004;109:433-438.
217. Haring R, Volzke H, Steveling A, et al: Low serum testosterone levels are associated with
increased risk of mortality in a population-based cohort of men aged 20-79. Eur.Heart J.
2010;31:1494-1501.
154
Reference List
218. Malkin CJ, Pugh PJ, Morris PD, et al: Low serum testosterone and increased mortality in men
with coronary heart disease. Heart 2010;96:1821-1825.
219. Ruige JB, Mahmoud AM, De BD, et al: Endogenous testosterone and cardiovascular disease
in healthy men: a meta-analysis. Heart 2011;97:870-875.
220. Rebuffe-Scrive M, Marin P, Bjorntorp P: Effect of testosterone on abdominal adipose tissue in
men. Int.J.Obes. 1991;15:791-795.
221. Kapoor D, Goodwin E, Channer KS, et al: Testosterone replacement therapy improves insulin
resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal
men with type 2 diabetes. Eur.J.Endocrinol. 2006;154:899-906.
222. Jones TH, Arver S, Behre HM, et al: Testosterone replacement in hypogonadal men with type
2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828-837.
223. Shores MM, Smith NL, Forsberg CW, et al: Testosterone treatment and mortality in men with
low testosterone levels. J.Clin.Endocrinol.Metab 2012;97:2050-2058.
224. Saad F, Haider A, Doros G, et al: Long-term treatment of hypogonadal men with testosterone
produces substantial and sustained weight loss. Obesity.(Silver.Spring) 2013;21:1975-1981.
225. Bots ML, Hoes AW, Koudstaal PJ, et al: Common carotid intima-media thickness and risk of
stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:1432-1437.
226. Nuzzo S, Lafage-Proust MH, Martin-Badosa E, et al: Synchrotron radiation microtomography
allows the analysis of three-dimensional microarchitecture and degree of mineralization
of human iliac crest biopsy specimens: effects of etidronate treatment. J.Bone Miner.Res.
2002;17:1372-1382.
227. Lee GK, Lee LC, Liu CW, et al: Framingham risk score inadequately predicts cardiac risk
in young patients presenting with a first myocardial infarction. Ann.Acad.Med.Singapore
2010;39:163-167.
228. Marin P, Holmang S, Gustafsson C, et al: Androgen treatment of abdominally obese men.
Obes.Res. 1993;1:245-251.
229. Anderson FH, Francis RM, Faulkner K: Androgen supplementation in eugonadal men with
osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk
factors. Bone 1996;18:171-177.
230. Boyanov MA, Boneva Z, Christov VG: Testosterone supplementation in men with type 2
diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6:1-7.
231. Heufelder AE, Saad F, Bunck MC, et al: Fifty-two-week treatment with diet and exercise plus
transdermal testosterone reverses the metabolic syndrome and improves glycemic control
in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J.Androl
2009;30:726-733.
232. Gietema JA, Sleijfer DT, Willemse PH, et al: Long-term follow-up of cardiovascular risk factors
in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann.
Intern.Med. 1992;116:709-715.
155
Appendices
Abbreviations
α-FPalpha-fetoprotein
ALAT alanine aminotransferase
AP alkaline phosphatase
ASAT aspartate aminotransferase
AUC7
seven times the area under the curve (carboplatin dose)
β-CTX
beta-carboxyl-terminal cross-linking telopeptide of type I collagen
β-HCG beta unit of human chorionic gonadotrophin
BEP bleomycin, etoposide and cisplatin combination chemotherapy
BMD bone mineral density
BMI body mass index
CIS carcinoma in situ
CRP C-reactive protein
CT chemotherapy
CTGCT
contralateral (metachronous) testicular germ cell tumour
CVA cerebrovascular accident
CVD
cardiovascular disease
DXA dual-energy X-ray absorptiometry
E2estradiol
EDV end-diastolic volume
EF ejection fraction
EP
etoposide and cisplatin combination chemotherapy
E/A ratio early and atrial filling velocities across the mitral valve
FRS Framingham Risk Score
FSH follicle-stimulating hormone
FT free testosterone
GCT
germ cell tumour
HDL high-density lipoprotein
1
H-MRS proton magnetic resonance spectroscopy
HOMA homeostatic model assessment
HTC hepatic triglyceride content
156
Abbreviations
IDF International Diabetes Federation
IGCCCG International Germ Cell Cancer Collaborative Group
IQR interquartile range
LDH lactate dehydrogenase
LDL low-density lipoprotein
LH luteinizing hormone
LIBC latent iron-binding capacity
LSMs
least square means
LUMC Leiden University Medical Center
LV left ventricular
LVED
left ventricular end-diastolic mass
MetS metabolic syndrome
MRI magnetic resonance imaging
MR-PWV magnetic resonance measured pulse wave velocity
NASH non-alcoholic steatohepatitis
NCEP-ATPIII Adult Treatment Panel of the National Cholesterol Education Program
NHANES
National Health and Nutrition Examination Surveys
NPBI non-protein bound iron
NSGCT non-seminoma germ cell tumour
NTA nitrilotriacetate
NTBI non-transferrin bound iron
PTH
parathyroid hormone
PVB
cisplatin, vinblastin and bleomycin combination chemotherapy
PWV pulse wave velocity
P1NP
procollagen type 1 N-terminal propeptide
RR blood pressure
RT radiotherapy
RV right ventricular
SCORE Systemic Coronary Risk Evaluation
SGCT seminoma germ cell tumour
SHBG sex hormone binding globulin
157
Appendices
TC testicular cancer
TGC triglyceride
TGCT
testicular germ cell tumour
TT total testosterone
VF vertebral fracture
WBC
white blood cell count
WHO World Health Organization
γ-GT gamma-glutamyl transferase
1,25(OH)2D3
1,25-dihydroxy vitamin-D3
25(OH)D3
25-hydroxy vitamin-D3
158
Abbreviations
159
Appendices
160
Acknowledgements
Acknowledgements
Beste Susanne, ik wil jou enorm bedanken voor je begeleiding de afgelopen jaren.
Ik kijk met veel plezier terug op onze samenwerking en alle overleg dat zelfs op de
meest onmogelijke tijden kon plaats vinden.
Beste Koos, je inbreng zorgde altijd voor eenvoud en overzicht. Daarnaast was je
kritische blik van buiten de kliniek voor mij een stimulans om de resultaten breder te
interpreteren.
Dear Neveen, we could fill a library with all the corrigenda. I really appreciate that you
taught me how to verbalize the scientific results. I do realise, however, that this is an
understatement for the efforts you put in my thesis.
Bij het doen van onderzoek naast een full time baan is de hulp van een oncologie
verpleegkundige onontbeerlijk. Jeanne, bedankt voor alle werk dat je mij uit handen
hebt genomen.
Beste Rutger, Bas en Saskia: de MRI onderzoeken op de afdeling radiologie waren
niet mogelijk geweest zonder jullie toegewijde hulp.
Ik wil alle patiënten hartelijk bedanken voor hun participatie in de studies beschreven
in dit proefschrift.
Go en Lot, jullie hebben altijd vertrouwen gehad in mijn wetenschappelijke
capaciteiten. Dubbel trapeze spinakerzeilen blijft een grote uitdaging!
Pierre, je voortdurende interesse heeft mij geholpen om het onderzoek naar
een hoger niveau te brengen. Niemand anders kon met zoveel plezier naar mijn
onderzoeksresultaten luisteren. Het enthousiasme waarmee je nieuwe ideeën
aanreikt werkt aanstekelijk.
Lieve Conny, jij hebt mij geleerd om nuchter tegen de zaken aan te kijken. Dit
proefschrift is daar een voorbeeld van.
De bemanning van de Bornrif wens ik immer een behouden vaart.
Lieve Sanne, zonder jouw steun was dit nooit gelukt. De uren achter mijn computer
hebben een zware belasting gelegd op de spaarzame vrije tijd samen, maar je
hebt mij alle ruimte gegeven om dit “boekje” af te schrijven. Het wordt tijd om onze
gezamenlijke energie in nieuwe doelen te steken.
161
Appendices
162
Curriculum Vitae
Curriculum Vitae
Peter-Paul Michiel Willemse (1978, Rotterdam) graduated in 1998 at the athenaeum
of “Het Nassau College” in Assen. Subsequently he studied chemistry for one year
and from 1999 onwards he studied medicine at Leiden University, The Netherlands.
He qualified as MD from Leiden University in November 2006. During his studies he
was treasurer of the board of the Leiden University Medical Students Congres and
chairman of the Leiden Student Sailing Association of the student fraternity ‘Minerva’.
In 2007 he started collecting data for studies that led to a formal PhD project at the
Department of Clinical Oncology of the Leiden University Medical Center under the
supervision of Prof. Dr. S. Osanto. Between 2008 and 2010 he was employed as a
physician at the department of surgery of the Leiden University Medical Center and
at the Departments of urology of two large peripheral hospitals (HagaZiekenhuis and
Medisch Centrum Haaglanden) in The Hague, The Netherlands.
He started his residency in urology in 2011, first at the Department of surgery of the
Reinier de Graaf Hospital in Delft (supervision by Dr. M. van der Elst) and from 2013
onwards at the Erasmus Medical Center in Rotterdam under the supervision of Dr.
P.C.M.S. Verhagen.
He lives with Sanne Kloosterman in Rotterdam.
163
Appendices
List of Publications
PM Willemse, L van Wulften, AQ van Steijn-van Tol, NA Hamdy and S Osanto. Bone
abnormalities in male germ-cell cancer survivors. J Clin Oncol, Vol 25, No 18S, 2007:
5053.
NI Weijl, PM Willemse, AQ Van Steijn-Van Tol, R Kolb, J Burggraaf and S Osanto.
Serum non protein-bound iron in testicular cancer patients treated with BEP
chemotherapy. J Clin Oncol, Vol 28, 2010 (suppl; abstr e13148).
PM Willemse, NA Hamdy, L van Wulften, AQ van Steijn-van Tol, H Putter and S
Osanto. Prevalence of vertebral fractures independent of BMD and anti-cancer
treatment in patients with testicular germ cell tumours. J Clin Endocrinol Metab,
2010 Nov; 95(11):4933-42.
PM Willemse, RW van der Meer, SG van Elderen, J Burggraaf, HJ Lamb, A de Roos
and S Osanto. Changes in body fat and lipid metabolism in testicular cancer patients
undergoing curative chemotherapy. J Clin Oncol, Vol 30, 2012 (suppl 5; abstr 337).
RW van der Meer, PM Willemse, LD van Schinkel, S Osanto, J Burggraaf, SG van
Elderen, A de Roos and HJ Lamb. Unfavorable metabolic changes are accompanied
by impaired myocardial function shortly after chemotherapy. Journal of Cardiovascular
Magnetic Resonance 2013, 15(Suppl 1):O46.
PM Willemse, J Burggraaf, NA Hamdy, NI Weijl, CY Vossen, L van Wulften, AQ van
Steijn-van Tol, FR Rosendaal and S Osanto. Prevalence of the Metabolic Syndrome
and Cardiovascular Disease Risk in chemotherapy-treated testicular germ cell
tumour survivors. Br.J.Cancer. 2013 Jul 9;109(1):60-7.
PM Willemse, J Burggraaf, NA Hamdy, NI Weijl, CY Vossen, L van Wulften, AQ van
Steijn-van Tol, FR Rosendaal and S Osanto. Prevalence of the Metabolic Syndrome
and Cardiovascular Disease Risk in chemotherapy-treated testicular germ cell
tumour survivors. Br.J.Cancer. 2013 Jul 9;109(1):295-6.
LD van Schinkel, PM Willemse, RW van der Meer, J Burggraaf, SG van Elderen,
JW Smit, A de Roos, S Osanto and HJ Lamb. Chemotherapy for testicular cancer
induces acute alterations in diastolic heart function. Br.J.Cancer. 2013 Aug 20;
109(4):891-6.
164
List of Publications
PM Willemse, RW van der Meer, J Burggraaf, SG van Elderen, ML de Kam, A de
Roos, HJ Lamb and S Osanto. Abdominal visceral and subcutaneous fat increase,
insulin resistance and hyperlipidemia in testicular cancer patients treated with
cisplatin-based chemotherapy. Acta Oncol. 2013 Aug 19. [Epub ahead of print]
PM Willemse, Burggraaf J, Hamdy NAT and S Osanto. Reply: ‘Comments on
Prevalence of the Metabolic Syndrome and Cardiovascular Disease Risk in
chemotherapy-treated testicular germ cell tumour survivors’. Br.J.Cancer. 2013 Oct
29; 109(9): 2503-4.
LD van Schinkel, PM Willemse, RW van der Meer, J Burggraaf, SG van Elderen, JW
Smit, A de Roos, S Osanto and HJ Lamb. Reply: Comment on ‘Chemotherapy for
testicular cancer induces acute alterations in diastolic heart function’. Br J Cancer.
2014 Jan 7; 110(1): 265.
165
Download
Related flashcards

Oncology

38 cards

Oncology

48 cards

Cancer organizations

24 cards

Tumor markers

14 cards

Tumor markers

15 cards

Create Flashcards